Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Sees Large Decrease in Short Interest

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the recipient of a large decrease in short interest during the month of December. As of December 31st, there was short interest totaling 11,149,487 shares, a decrease of 17.6% from the December 15th total of 13,528,238 shares. Based on an average daily volume of 11,616,018 shares, the short-interest ratio is currently 1.0 days. Currently, 14.0% of the shares of the stock are sold short. Currently, 14.0% of the shares of the stock are sold short. Based on an average daily volume of 11,616,018 shares, the short-interest ratio is currently 1.0 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. CIBC Bancorp USA Inc. purchased a new stake in shares of Aspire Biopharma in the third quarter valued at about $28,000. Jane Street Group LLC boosted its holdings in Aspire Biopharma by 625.8% in the 2nd quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock valued at $41,000 after purchasing an additional 131,533 shares during the last quarter. Optivise Advisory Services LLC grew its stake in shares of Aspire Biopharma by 120.9% in the 2nd quarter. Optivise Advisory Services LLC now owns 235,106 shares of the company’s stock valued at $63,000 after buying an additional 128,660 shares during the period. Finally, Crewe Advisors LLC grew its stake in shares of Aspire Biopharma by 100.0% in the 2nd quarter. Crewe Advisors LLC now owns 626,854 shares of the company’s stock valued at $169,000 after buying an additional 313,427 shares during the period. Institutional investors and hedge funds own 19.17% of the company’s stock.

Aspire Biopharma Price Performance

ASBP opened at $2.21 on Monday. The firm has a market capitalization of $5.94 million, a price-to-earnings ratio of -4.42 and a beta of 0.81. The company’s 50 day simple moving average is $4.07 and its two-hundred day simple moving average is $11.74. Aspire Biopharma has a 1-year low of $1.65 and a 1-year high of $632.00.

Aspire Biopharma (NASDAQ:ASBP) last posted its quarterly earnings results on Friday, November 14th. The company reported ($1.60) earnings per share (EPS) for the quarter. The firm had revenue of $0.00 million during the quarter.

Analysts Set New Price Targets

ASBP has been the subject of several research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aspire Biopharma in a research note on Wednesday, October 8th. Wall Street Zen raised Aspire Biopharma to a “sell” rating in a research note on Saturday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

About Aspire Biopharma

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.